![Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/5944/TOC-Subject-Sample-2021-Medicine-Dentistry-Nursing-Allied-Health.jpg"})
Abstract
Novelty: The use of BRL 38227 (levcromakalim)(3S,4R-6-cyano-3,4-dihydro-2,2-dimethyl-4-(2-oxopyrrolidin- 1 -yl)-2H- 1 -benzopyran-3-01) a known K+ channel activator as a method for the prophylaxis and treatment of hyperlipidaemia is claimed.
Biology: The lipid profile of BRL 38227 is presented as the percentage change from baseline following eight weeks of treatment. A dose of 1.5 mg lowered total cholesterol by 6.2% (placebo, 4.2% increase in total cholesterol).
Chemistry: The synthesis of BRL 38227 is known and is not described. Its use in combination with a β-blocker or diuretic is claimed.